ORX Stock Overview
A specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Orexo AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 16.48 |
| 52 Week High | SEK 23.30 |
| 52 Week Low | SEK 13.32 |
| Beta | 0.65 |
| 11 Month Change | -21.52% |
| 3 Month Change | 4.44% |
| 1 Year Change | -13.35% |
| 33 Year Change | -56.05% |
| 5 Year Change | -75.98% |
| Change since IPO | -81.69% |
Recent News & Updates
Recent updates
Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price
Jul 20
Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward
May 29Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry
Apr 03We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt
Dec 09Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price
Jun 14Is Orexo (STO:ORX) A Risky Investment?
Apr 27Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price
Oct 19Would Orexo (STO:ORX) Be Better Off With Less Debt?
Sep 09Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?
May 26Is Orexo (STO:ORX) Using Too Much Debt?
Apr 16Orexo (STO:ORX) Has Debt But No Earnings; Should You Worry?
May 04Increases to Orexo AB (publ)'s (STO:ORX) CEO Compensation Might Cool off for now
Apr 06Shareholder Returns
| ORX | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -17.6% | -2.6% | -1.8% |
| 1Y | -13.4% | 75.3% | 14.4% |
Return vs Industry: ORX underperformed the Swedish Pharmaceuticals industry which returned 75.3% over the past year.
Return vs Market: ORX underperformed the Swedish Market which returned 14.4% over the past year.
Price Volatility
| ORX volatility | |
|---|---|
| ORX Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 11.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.5% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: ORX's share price has been volatile over the past 3 months.
Volatility Over Time: ORX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 113 | Nikolaj Sorensen | www.orexo.com |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis.
Orexo AB (publ) Fundamentals Summary
| ORX fundamental statistics | |
|---|---|
| Market cap | SEK 568.63m |
| Earnings (TTM) | -SEK 96.60m |
| Revenue (TTM) | SEK 615.20m |
0.9x
P/S Ratio-5.9x
P/E RatioIs ORX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORX income statement (TTM) | |
|---|---|
| Revenue | SEK 615.20m |
| Cost of Revenue | SEK 72.50m |
| Gross Profit | SEK 542.70m |
| Other Expenses | SEK 639.30m |
| Earnings | -SEK 96.60m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 24, 2024
| Earnings per share (EPS) | -2.80 |
| Gross Margin | 88.22% |
| Net Profit Margin | -15.70% |
| Debt/Equity Ratio | 2,373.6% |
How did ORX perform over the long term?
See historical performance and comparison